ReviewCureus2026
Diagnostic Accuracy and Prognostic Value of Flow Cytometry Versus PCR-Based Minimal Residual Disease Assessment in Leukemia: A Systematic Review and Meta Analysis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Measurable/minimal residual disease (MRD) is the most critical prognostic biomarker in leukemia. Multiparameter flow cytometry (MFC) and polymerase chain reaction (PCR)-based assays are the clinical standards for MRD detection; however, inter-method discordance complicates the clinical decision-making process. A systematic review and meta-analysis were conducted to evaluate the diagnostic accuracy of MFC compared to PCR and to delineate the prognostic significance of discordant MRD results. Following the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guidelines, major databases were systematically searched for studies comparing MFC and PCR-based MRD assessments in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Diagnostic test accuracy was pooled using a bivariate random-effects model, and prognostic hazard ratios were synthesized using the restricted maximum likelihood models. Twenty-three non-randomized studies met the inclusion criteria of this review. In the diagnostic meta-analysis (12 studies), MFC demonstrated a pooled sensitivity of 76.2% (95% CI, 55.2-89.3) and a high pooled specificity of 96.0% (95% CI, 93.2-97.7) when compared with PCR, yielding an excellent area under the curve (AUC) of 0.965. Meta-regression identified leukemia subtype as a significant moderator (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.